Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center-Reference-Cited by-同舟云学术

Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center

Published:2024-04-26 Issue:1 Volume:29 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Hao Ziyi¹,Fei Yingying²,Chen Juan³,Huang Sailan¹,Wang Li¹,Yu Youhuan¹,Bian Meiru¹,Si Yejun¹,Zhang Xingxia¹,Yang Xiaotian¹,Zhang Bing¹,Wan Yan¹,Lin Guoqiang¹,Zhang Yanming¹

Affiliation:

1. Department of Hematology, Huai'an Hospital Affiliated to Xuzhou Medical College and Huai'an Second People's Hospital, Huai'an, People’s Republic of China

2. Department of Radiotherapy, Huai'an Hospital Affiliated to Xuzhou Medical College and Huai'an Second People's Hospital, Huai'an, People’s Republic of China

3. Department of Hematology, Siyang Hospital of Traditional Chinese Medicine, Suqian, People’s Republic of China

Funder

General Project of Jiangsu Health Commission

Senile Health Scientific Research Project of Jiangsu Province

Research Project of Natural Science Foundation of Huai an, Jiangsu

Research Project of Jiangsu Provincial Bureau of Traditional Chinese Medicine Jiangsu

Province key Laboratory opening project

Sample bank of biological resources of major diseases in Jiangsu Province

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2024.2344998

Reference29 articles.

1. Outcome of adults with acute lymphocytic leukemia after second salvage therapy

2. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

3. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy

4. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances

5. Bcl-2–family proteins and hematologic malignancies: history and future prospects